Citadel Advisors
KROS icon

Citadel Advisors’s Keros Therapeutics KROS Stock Holding History

Citadel Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.49M Sell
406,666
-65,854
-14% -$1.02M ﹤0.01% 4521
2025
Q4 		$9.62M Buy
472,520
+296,376
+168% +$5.2M ﹤0.01% 3301
2025
Q3 		$2.79M Buy
176,144
+153,246
+669% +$2.26M ﹤0.01% 5437
2025
Q2 		$306K Sell
22,898
-168,711
-88% -$2.28M ﹤0.01% 9771
2025
Q1 		$1.95M Sell
191,609
-599,500
-76% -$6.96M ﹤0.01% 5576
2024
Q4 		$12.5M Buy
791,109
+86,186
+12% +$4.48M ﹤0.01% 2696
2024
Q3 		$40.9M Buy
704,923
+294,439
+72% +$14.5M 0.01% 1401
2024
Q2 		$18.8M Sell
410,484
-39,794
-9% -$2.14M ﹤0.01% 2063
2024
Q1 		$29.8M Sell
450,278
-309,890
-41% -$18.4M 0.01% 1669
2023
Q4 		$30.2M Buy
760,168
+355,019
+88% +$11.1M 0.01% 1615
2023
Q3 		$12.9M Buy
405,149
+77,349
+24% +$2.89M ﹤0.01% 2363
2023
Q2 		$13.2M Sell
327,800
-43,683
-12% -$1.91M ﹤0.01% 2341
2023
Q1 		$15.9M Sell
371,483
-33,988
-8% -$1.72M ﹤0.01% 2194
2022
Q4 		$19.5M Sell
405,471
-22,636
-5% -$1.06M ﹤0.01% 1996
2022
Q3 		$16.1M Buy
428,107
+73,753
+21% +$2.56M ﹤0.01% 2128
2022
Q2 		$9.79M Buy
354,354
+74,193
+26% +$3.26M ﹤0.01% 2716
2022
Q1 		$15.2M Buy
280,161
+3,059
+1% +$157K ﹤0.01% 2342
2021
Q4 		$16.2M Buy
277,102
+2,777
+1% +$138K ﹤0.01% 2300
2021
Q3 		$10.9M Buy
274,325
+156,377
+133% +$5.57M ﹤0.01% 2945
2021
Q2 		$5.01M Sell
117,948
-9,977
-8% -$540K ﹤0.01% 4429
2021
Q1 		$7.87M Sell
127,925
-141,318
-52% -$8.95M ﹤0.01% 3361
2020
Q4 		$19M Buy
+269,243
New +$17M ﹤0.01% 1858
2020
Q3 		– Sell
-157,333
Closed -$5.9M – 10435
2020
Q2 		$5.9M Buy
+157,333
New +$4.85M ﹤0.01% 2861

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Citadel Advisors's KROS Position: Q1 2026 in Review

Citadel Advisors reduced its Keros Therapeutics (KROS) stake by 14% in Q1 2026, selling an estimated $1.02M and leaving 406,666 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #4521.

Citadel Advisors first reported a position in KROS in Q2 2020 and has held it in 23 quarters since. The position peaked at $40.9M in Q3 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Citadel Advisors held 406,666 shares of Keros Therapeutics worth $4.49M as of Q1 2026.
  • Citadel Advisors sold 65,854 Keros Therapeutics shares in Q1 2026, an estimated $1.02M.
  • Keros Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4521 holding.
  • Citadel Advisors first reported a position in Keros Therapeutics in Q2 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Keros Therapeutics position peaked at $40.9M in Q3 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.